Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes

Handbook of Experimental Pharmacology

Volumn 203, Issue , 2011, Pages 75-104

  Di Marzo, Vincenzo ^a   Piscitelli, Fabiana ^a   Mechoulam, Raphael ^b  

^a CNR   (Italy)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Endocannabinoid; Lipids; Phytocannabinoid; Rimonabant

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 4 AMINOBUTYRIC ACID; ANANDAMIDE; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; CORTICOSTERONE; CORTICOTROPIN RELEASING FACTOR; DRONABINOL; ENDOCANNABINOID; GAMMA INTERFERON; GHRELIN; GLIMEPIRIDE; GLUCOSE; INSULIN; INTERLEUKIN 4; LEPTIN; LIPID; MELANIN CONCENTRATING HORMONE; METFORMIN; OTENABANT; PLACEBO; PROOPIOMELANOCORTIN; RIMONABANT; SULFONYLUREA; TARANABANT; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; CANNABINOID; CANNABIS;

ABDOMINAL OBESITY; ADIPOSE TISSUE; ANXIETY DISORDER; ATHEROSCLEROSIS; AUTOIMMUNITY; BRAIN NUCLEUS; CALORIC INTAKE; CARDIOVASCULAR RISK; CELL DAMAGE; CYTOKINE PRODUCTION; DEPRESSION; DIARRHEA; DIET RESTRICTION; DIZZINESS; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENERGY BALANCE; ENERGY EXPENDITURE; EXERCISE; FATTY LIVER; FOOD INTAKE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INHIBITION KINETICS; INSULIN DEPENDENT DIABETES MELLITUS; LIPID METABOLISM; LIPOGENESIS; LIPOLYSIS; MAMMAL; MEDICAL RESEARCH; METABOLIC SYNDROME X; NAUSEA; NEUROTRANSMITTER RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SATIETY; SIGNAL TRANSDUCTION; WEIGHT REDUCTION; CHEMISTRY; DIABETES MELLITUS; DRUG ANTAGONISM; ENERGY METABOLISM; METABOLIC DISORDER; PATHOPHYSIOLOGY; PHYSIOLOGY;

CANNABINOIDS; CANNABIS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; ENDOCANNABINOIDS; ENERGY METABOLISM; HUMANS; METABOLIC DISEASES; RECEPTOR, CANNABINOID, CB1;

EID: 79955632246     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-17214-4_4     Document Type: Review

References (138)

1. Anderson MS, Bluestone JA (2005) The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 23:447-485 (Pubitemid 40563177)
2. Annuzzi G, Piscitelli F, Di Marino L et al (2010) Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients. Lipids Health Dis 9:43
3. Ashton JC, Friberg D, Darlington CL et al (2006) Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neurosci Lett 396:113-116 (Pubitemid 43276423)
4. Atkinson MA, Leiter EH (1999) The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 5:601-604
5. Bellocchio L, Cervino C, Vicennati V et al. (2008) Cannabinoid type 1 receptor: another arrow in the adipocytes' bow. J Neuroendocrinol Suppl 1:130-138 (Review)
6. Bensaid M, Gary-Bobo M, Esclangon A et al (2003) The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63:908-914 (Pubitemid 36368998)
7. Ben-Shabat S, Fride E, Sheskin T et al (1998) An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 353:23-31 (Pubitemid 28352285)
8. Bermudez-Silva FJ, Serrano A, Diaz-Molina FJ et al (2006) Activation of cannabinoid CB(1) receptors induces glucose intolerance in rats. Eur J Pharmacol 531:282-284 (Pubitemid 43202248)
9. Bermúdez-Silva FJ, Suárez J, Baixeras E et al (2008) Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia 51:476-487
10. Bilfinger TV, Salzet M, Fimiani C, Deutsch DG, Tramu G, Stefano GB (1998) Pharmacological evidence for anandamide amidase in human cardiac and vascular tissues. Int J Cardiol 64 (Suppl 1):S15-S22 (Pubitemid 28293460)
11. Bisogno T, Melck D, De Petrocellis L et al (1999) Phosphatidic acid as the biosynthetic precursor of the endocannabinoid 2-arachidonoylglycerol in intact mouse neuroblastoma cells stimulated with ionomycin. J Neurochem 72:2113-2119 (Pubitemid 29186018)
12. Bisogno T, Howell F, Williams G et al (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 163:463-468 (Pubitemid 37429860)
13. Bluher M, Engeli S, Kloting N et al (2006) Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 55:3053-3060 (Pubitemid 44923642)
14. Bouaboula M, Hilairet S, Marchand J et al (2005) Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur J Pharmacol 517:174-181 (Pubitemid 40977892)
15. Burdyga G, Lal S, Varro A et al (2004) Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci 24:2708-2715 (Pubitemid 38380947)
16. Cavuoto P, McAinch AJ, Hatzinikolas G et al (2007) Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Mol Cell Endocrinol 267:63-69
17. Chambers AP, Sharkey KA, Koopmans HS (2004) Cannabinoid (CB)1 receptor antagonist, AM 251, causes a sustained reduction of daily food intake in the rat. Physiol Behav 82:863-869 (Pubitemid 39297082)
18. Colombo G, Agabio R, Diaz G et al (1998) Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 63:113-117 (Pubitemid 28378339)
19. Cota D, Marsicano G, Tschop M et al (2003) The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112:423-431 (Pubitemid 38063771)
20. Cota D, Tschop MH, Horvath TL et al (2006) Cannabinoids, opioids and eating behavior: the molecular face of hedonism? Brain Res Rev 51:85-107
21. Cota D, Steiner MA, Marsicano G et al (2007) Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function. Endocrinology 148: 1574-1581 (Pubitemid 46457104)
22. Cote M, Matias I, Lemieux I et al (2007) Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 31:692-699 (Pubitemid 46482358)
23. Coutts AA, Izzo AA (2004) The gastrointestinal pharmacology of cannabinoids: an update. Curr Opin Pharmacol 4:572-579 (Pubitemid 40267871)
24. Cravatt BF, Giang DK, Mayfield SP et al (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384:83-87 (Pubitemid 26374593)
25. De Petrocellis L, Marini P, Matias I et al (2007) Mechanisms for the coupling of cannabinoid receptors to intracellular calcium mobilization in rat insulinoma beta-cells. Exp Cell Res 313:2993-3004 (Pubitemid 47135571)
26. De Petrocellis L, Vellani V, Schiano-Moriello A et al (2008) Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J Pharmacol Exp Ther 325:1007-1015 (Pubitemid 351724325)
27. D'Eon TM, Pierce KA, Roix JJ et al (2008) The role of adipocyte insulin resistance in the pathogenesis of obesity-related elevations in endocannabinoids. Diabetes 57:1262-1268
28. Després JP, Lemieux I (2006) Abdominal obesity and metabolic syndrome. Nature 444:881-887
29. Després JP, Golay A, Sjöström L et al (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121-2134 (Pubitemid 41653104)
30. Devane WA, Dysarz FA, Johnson MR et al (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605-613 (Pubitemid 19007296)
31. Devane WA, Hanus L, Breuer A et al (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949 (Pubitemid 23026736)
32. Di Marzo V (2008a) Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7:438-455
33. Di Marzo V (2008b) The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 51:1356-1367
34. Di Marzo V, Després JP (2010) CB1 antagonists for obesity-what lessons have we learned from rimonabant? Nat Rev Endocrinol 5:633-638
35. Di Marzo V, De Petrocellis L, Sugiura T et al (1996) Potential biosynthetic connections between the two cannabimimetic eicosanoids, anandamide and 2-arachidonoyl-glycerol, in mouse neuroblastoma cells. Biochem Biophys Res Commun 227:281-288 (Pubitemid 26370588)
36. Di Marzo V, Sepe N, De Petrocellis L et al (1998) Trick or treat from food endocannabinoids? Nature 396:636-637
37. Di Marzo V, Goparaju SK, Wang L et al (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410:822-825 (Pubitemid 32303781)
38. Di Marzo V, Bifulco M, De Petrocellis L (2004) The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3:771-784 (Pubitemid 39242829)
39. Di Marzo V, De Petrocellis L, Di Marzo V, De Petrocellis L (2005) Non-CB1, non-CB2 receptors for endocannabinoids. In: Onaivi ES, Sugiura T, Di Marzo V (eds) Endocannabinoids: The Brain and Body's Marijuana and Beyond. CRC Press, Taylor & Francis Group, Boca Raton, FL, pp 151-174
40. Di Marzo V, Côté M, Matias I et al (2009a) Changes in plasma endocannabinoid levels in viscerally obese men following a one-year lifestyle modification program and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia 52:213-217
41. Di Marzo V, Verrijken A, Hakkarainen A et al (2009b) Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol 161:715-722
42. Dinh TP, Carpenter D, Leslie FM et al (2002) Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 99:10819-10824
43. DiPatrizio NV, Simansky KJ (2008a) Activating parabrachial cannabinoid CB1 receptors selectively stimulates feeding of palatable foods in rats. J Neurosci 28:9702-9709
44. Dipatrizio NV, Simansky KJ (2008) Inhibiting parabrachial fatty acid amide hydrolase activity selectively increases the intake of palatable food via cannabinoid CB1 receptors. Am J Physiol Regul Integr Comp Physiol [Epub ahead of print]
45. Doyon C, Denis RG, Baraboi ED et al (2006) Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitary-adrenal axis and neuronal activation in lean and obese Zucker rats. Diabetes 55:3403-3410 (Pubitemid 44923599)
46. Ellis J, Pediani JD, Canals M et al (2006) Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J Biol Chem 281:38812-38824 (Pubitemid 46042008)
47. Engeli S, Bohnke J, Feldpausch M et al (2005) Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54:2838-2843 (Pubitemid 41401077)
48. Esposito I, Proto MC, Gazzerro P et al (2008) The cannabinoid CB1 receptor antagonist Rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating phosphatidylinositol- 3-kinase activity. Mol Pharmacol 74(6):1678-1686
49. Fride E, Ginzburg Y, Breuer A et al (2001) Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. Eur J Pharmacol 419:207-214 (Pubitemid 32568220)
50. Gallate JE, Saharov T, Mallet PE et al (1999) Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist. Eur J Pharmacol 370:233-240 (Pubitemid 29192867)
51. Gaoni Y, Mechoulam R (1964) Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem So 86:1646-1647
52. Gary-Bobo M, Elachouri G, Scatton B et al (2006) The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 69:471-478 (Pubitemid 43121944)
53. Gary-Bobo M, Elachouri G, Gallas JF et al (2007) Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 46:122-129 (Pubitemid 47171928)
54. Gasperi V, Fezza F, Pasquariello N et al (2007) Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell Mol Life Sci 64:219-229 (Pubitemid 46155701)
55. Getty-Kaushik L, Richard A-MT, Deeney JT, Shirihai O, Corkey B (2009) The CB1 antagonist, rimonabant, decreases insulin hypersecretion in rat pancreatic islets. Obesity 17:1856-1860
56. Glass M, Northup JK (1999) Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. Mol Pharmacol 56:1362-1369
57. Gomez R, Navarro M, Ferrer B et al (2002) A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 22:9612-9617 (Pubitemid 35356203)
58. Gong JP, Onaivi ES, Ishiguro H et al (2006) Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 1071:10-23 (Pubitemid 43255471)
59. Gonzalez S, Manzanares J, Berrendero F et al (1999) Identification of endocannabinoids and cannabinoid CB(1) receptor mRNA in the pituitary gland. Neuroendocrinology 70:137-145 (Pubitemid 29385394)
60. Hanus L, Mechoulam R (2008) Plant and brain cannabinoids: The chemistry of major new players in physiology. In: Ikan R (ed) Selected topics in the chemistry of natural products. World Scientific Publishing Company. Imperial College Press, London, pp 49-75
61. Hanus L, Avraham Y, Ben-Shushan D et al (2003) Short term fasting and prolonged semistarvation have opposite effect on 2-AG levels in mouse brain. Brain Res 983:144-151 (Pubitemid 36952575)
62. Herling AW, Gossel M, Haschke G et al (2007) CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats. Am J Physiol Endocrinol Metab 293:E826-E832 (Pubitemid 47358996)
63. Herling AW, Kilp S, Elvert R et al (2008a) Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats. Endocrinology 149:2557-2566 (Pubitemid 351574492)
64. Herling AW, Kilp S, Juretschke HP et al (2008b) Reversal of visceral adiposity in candy-diet fed female Wistar rats by the CB1 receptor antagonist rimonabant. Int J Obes (Lond) 32:1363-1372
65. Hilairet S, Bouaboula M, Carrière D et al (2003) Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716. J Biol Chem 278:23731-23737
66. Hollander PA, Amod A, Litwak LE, Chaudhari U; ARPEGGIO Study Group (2010) Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial. Diabetes Care 33:605-607
67. Izzo AA, Piscitelli F, Capasso R et al (2009) Peripheral endocannabinoid dysregulation in two experimental models of obesity: potential relationships with intestinal motility and food deprivation/refeeding-induced energy processing. Br J Pharmacol 158:451-461
68. Janiak P, Poirier B, Bidouard JP et al (2007) Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int 72 (11):1345-1357 (Pubitemid 350126778)
69. Jbilo O, Ravinet-Trillou C, Arnone M et al (2005) The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 19:1567-1569 (Pubitemid 41279033)
70. Jo YH, Chen YJ, Chua SC Jr et al (2005) Integration of endocannabinoid and leptin signaling in an appetite-related neural circuit. Neuron 48:1055-1066
71. Juan-Pico P, Fuentes E, Bermudez-Silva FJ et al (2006) Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium 39:155-162 (Pubitemid 43013847)
72. Kirkham TC, Williams CM, Fezza F et al (2002) Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 136:550-557 (Pubitemid 34717699)
73. Klein TW (2005) Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5:400-411
74. Koch JE (2001) Delta(9)-THC stimulates food intake in Lewis rats: effects on chow, high-fat and sweet high-fat diets. Pharmacol Biochem Behav 68:539-543
75. Kola B, Hubina E, Tucci SA et al (2005) Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 280:25196-25201 (Pubitemid 40934612)
76. Kola B, Farkas I, Christ-Crain M et al (2008) The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS ONE 3:1797
77. Kunz I, Meier MK, Bourson A et al (2008) Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats. Int J Obes (Lond) 32:863-70 (Pubitemid 351670628)
78. Leung D, Saghatelian A, Simon GM et al (2006) Inactivation of N-acyl phosphatidylethanolamine phospholipase d reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 45:4720-4726
79. Liu YL, Connoley IP, Wilson CA et al (2005) Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) 29:183-187 (Pubitemid 40188413)
80. Maccarrone M, Di Rienzo M, Finazzi-Agro A et al (2003) Leptin activates the anandamide hydrolase promoter in human T lymphocytes through STAT3. J Biol Chem 278:13318-13324 (Pubitemid 36800103)
81. Maccarrone M, Fride E, Bisogno T et al (2005) Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility. Mol Hum Reprod 11:21-28 (Pubitemid 40330999)
82. Malcher-Lopes R, Di S, Marcheselli VS et al (2006) Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. J Neurosci 26:6643-6650 (Pubitemid 44318346)
83. Mandrup-Poulsen T (2003) Beta cell death and protection. Ann NY Acad Sci 1005:32-42
84. Matias I, Di Marzo V (2007) Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 18:27-37 (Pubitemid 44960014)
85. Matias I, Gonthier MP, Orlando P et al (2006) Regulation, function and dysregulation of endocannabinoids in models of adipose and b-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91:3171-80 (Pubitemid 44271774)
86. Matias I, Petrosino S, Racioppi A et al (2008) Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets. Mol Cell Endocrinol 286:S66-78
87. McAllister SD, Glass M (2002) CB(1) and CB(2) receptor-mediated signaling: a focus on endocannabinoids. Prostaglandins Leukot Essent Fatty Acids 66:161-171 (Pubitemid 34743592)
88. McLaughlin PJ, Winston K, Swezey L et al (2003) The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav Pharmacol 14:583-588
89. Mechoulam R (1970) Marihuana chemistry. Science 168:1159-66
90. Mechoulam R (2005) Plant cannabinoids: a neglected pharmacological treasure trove. Br J Pharmacol 146:913-915
91. Mechoulam R, Hanus L (2002) Cannabidiol: An overview of some chemical and pharmacological aspects. Part I: Chemical Aspects Chem Phys Lipids 121:35-43 (Pubitemid 36044540)
92. Mechoulam R, Ben-Shabat S, Hanus L et al (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83-90
93. Mechoulam R, Parker LA, Gallily R (2002) Cannabidiol: An overview of some pharmacological aspects. J Clin Pharmacol 42:11S-19S
94. Mechoulam R, Berry EM, Avraham Y et al (2006) Endocannabinoids, feeding and suckling - from our perspective. Int J Obes (Lond) 30:S24-S28
95. Mechoulam R, Peters M, Murillo-Rodriguez E et al (2007) Cannabidiol - recent advances. Chem Biodivers 4:1678-1692 (Pubitemid 47377200)
96. Monteleone P, Matias I, Martiadis V et al (2005) Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology 30:1216-1221 (Pubitemid 40720981)
97. Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65 (Pubitemid 23305569)
98. Murdolo G, Kempf K, Hammarstedt A, Murdolo G, Kempf K, Hammarstedt A et al (2007) Insulin differentially modulates the peripheral endocannabinoid system in human subcutaneous abdominal adipose tissue from lean and obese individuals. J Endocrinol Invest 30:RC17-RC21
99. Nogueiras R, Veyrat-Durebex C, Suchanek PM et al (2008) Peripheral, but not central, CB1 antagonism provides food intake independent metabolic benefits in diet-induced obese rats. Diabetes 57(11):2977-2991
100. Okamoto Y, Morishita J, Tsuboi K et al (2004) Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 279:5298-5305 (Pubitemid 38220550)
101. Osei-Hyiaman D, Depetrillo M, Harvey-White J et al (2005a) Cocaine- and amphetamine-related transcript is involved in the orexigenic effect of endogenous anandamide. Neuroendocrinology 81:273-282 (Pubitemid 41397036)
102. Osei-Hyiaman D, DePetrillo M, Pacher P et al (2005b) Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115:1298-1305 (Pubitemid 40629049)
103. Osei-Hyiaman D, Liu J, Zhou L et al (2008) Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 118:3160-3169
104. Pagano C, Pilon C, Calcagno A et al (2007) The endogenous cannabinoid system stimulates glucose uptake in human fat cells via PI3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 92(12):4810-4819 (Pubitemid 350223464)
105. Pagotto U, Marsicano G, Cota D et al (2006) The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27:73-100 (Pubitemid 43228239)
106. Partosoedarso ER, Abrahams TP, Scullion RT et al (2003) Cannabinoid1 receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets. J Physiol 550:149-158 (Pubitemid 36869276)
107. Pi-Sunyer FX, Aronne LJ, Heshmati HM et al (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295:761-775 (Pubitemid 43244304)
108. Poirier B, Bidouard JP, Cadrouvele C et al (2005) The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 7:65-72
109. Qin N, Neeper MP, Liu Y et al (2008) TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci 28:6231-6238
110. Ravinet Trillou C, Arnone M, Delgorge C et al (2003) Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 284:345-353
111. Ravinet Trillou C, Delgorge C, Menet C et al (2004) CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 28:640-648 (Pubitemid 38491158)
112. Rinaldi-Carmona M, Barth F, Heaulme M et al (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244 (Pubitemid 24268029)
113. Robbe D, Kopf M, Remaury A et al (2002) Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci USA 99:8384-8388 (Pubitemid 34651061)
114. Roche R, Hoareau L, Bes-Houtmann S et al (2006) Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem Cell Biol 4:1-11
115. Rosenstock J, Hollander P, Chevalier S et al (2008) SERENADE trial: effects of monotherapy with rimonabant, the first selective cb1 receptor antagonist, on glycemic control, body weight and lipid profile in drug-naive type 2 diabetes. Diabetes Care 31(11):2169-2176
116. Ruby MA, Nomura DK, Hudak CS et al (2008) Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins. Proc Natl Acad Sci USA 105:14561-14566
117. Schäfer A, Pfrang J, Neumüller J et al (2008) The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats. Br J Pharmacol 154:1047-1054 (Pubitemid 351915060)
118. Scheen AJ, Finer N, Hollander P et al (2006) Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368:1660-1672 (Pubitemid 46048528)
119. Schlicker E, Kathmann M (2001) Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 22:565-572 (Pubitemid 33042646)
120. Soria-Gómez E, Matias I, Rueda-Orozco PE et al (2007) Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-Fos expression in the hypothalamus. Br J Pharmacol 151:1109-1116 (Pubitemid 47195529)
121. Starowicz K, Cristino L, Matias I et al (2008) Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed a high fat diet. Obesity 16(3):553-565 (Pubitemid 351328005)
122. Sugiura T, Kondo S, Sukagawa A et al (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215:89-97
123. Sun YX, Tsuboi K, Okamoto Y et al (2004) Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. Biochem J 380:749-756 (Pubitemid 38850516)
124. Tam J, Vemuri VK, Liu J et al (2010) Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 120:2953-2966
125. Thomas EA, Cravatt BF, Danielson PE et al (1997) Fatty acid amide hydrolase, the degradative enzyme for anandamide and oleamide, has selective distribution in neurons within the rat central nervous system. J Neurosci Res 50:1047-1052 (Pubitemid 28034660)
126. Thomas A, Stevenson LA, Wease KN et al (2005) Evidence that the plant cannabinoid Δ9- tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol 146:917-926 (Pubitemid 41722163)
127. Tsou K, Nogueron MI, Muthian S et al (1998) Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry. Neurosci Lett 254:137-140 (Pubitemid 28459400)
128. Tucci SA, Rogers EK, Korbonits M et al (2004) The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br J Pharmacol 143:520-533
129. Van Gaal LF, Rissanen AM, Scheen AJ et al (2005) Effects of the cannabinoid-1 receptor blocker Rimonabant on weight reduction and cardiovascular risk factors in overweight pationts: 1-year experience from the RIO-Europe study. Lancet 365:1389-1397 (Pubitemid 40523733)
130. Van Gaal L, Pi-Sunyer X, Després JP et al (2008) Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 31:S229-240
131. Van Sickle MD, Duncan M, Kingsley PJ et al (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310:329-332 (Pubitemid 41457202)
132. Weiss L, Zeira M, Reich S et al (2006) Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 39:143-151 (Pubitemid 43675258)
133. Weiss L, Zeira M, Reich S et al (2008) Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacol 54:244-249 (Pubitemid 350299408)
134. Williams CM, Kirkham TC (1999) Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacol (Berl) 143:315-317 (Pubitemid 29204987)
135. 9- THC. Physiol Behav 65:343-346
136. Wilson RI, Nicoll RA (2002) Endocannabinoid signaling in the brain. Science 296:678-682
137. Yan ZC, Liu DY, Zhang LL et al (2007) Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta. Biochem Biophys Res Commun 354:427-33 (Pubitemid 46172454)
138. Zimmer A, Zimmer AM, Hochmann AG (1999) Increased mortality, hypoactivity and hypoalgesia in cannabinoid CB1 receptor knockout mice. PNAS 96:5780-5785 (Pubitemid 29234695)